Superhumps in Low-Mass X-Ray Binaries

We propose a mechanism for the superhump modulations observed in optical photometry of at least two black hole X-ray transients (SXTs). As in extreme mass-ratio cataclysmic variables (CVs), superhumps are assumed to result from the presence of the 3:1 orbital resonance in the accretion disc. This causes the disc to become non-axisymmetric and precess. However the mechanism for superhump luminosity variations in low mass X-ray binaries (LMXBs) must differ from that in CVs, where it is attributed to a tidally-driven modulation of the disc's viscous dissipation, varying on the beat between the orbital and disc precession period. By contrast in LMXBs, tidal dissipation in the outer accretion disc is negligible: the optical emission is overwhelming dominated by reprocessing of intercepted central X-rays. Thus a different origin for the superhump modulation is required. Recent observations and numerical simulations indicate that in an extreme mass-ratio system the disc area changes on the superhump period. We deduce that the superhumps observed in SXTs arise from a modulation of the reprocessed flux by the changing area. Therefore, unlike the situation in CVs, where the superhump amplitude is inclination-independent, superhumps should be best seen in low-inclination LMXBs, whereas an orbital modulation from the heated face of the secondary star should be more prominent at high inclinations. Modulation at the disc precession period (10s of days) may indicate disc asymmetries such as warping. We comment on the orbital period determinations of LMXBs, and the possibility and significance of possible permanent superhump LMXBs.Comment: 6 pages, 1 encapsulated figure. MNRAS in press; replaced to correct typographical error

Cognitive Information Processing

Contains reports on one research project.National Science Foundation (Grant GK-3373X1)Joint Services Electronics Program (Contract DAAB07-71-C-0300)National Institutes of Health (Grant 5 P01 GM14940-07

Tau Aggregation Inhibitor Therapy : An Exploratory Phase 2 Study in Mild or Moderate Alzheimer's Disease

ACKNOWLEDGMENTS We thank patients and their caregivers for their participation in the study and are indebted to all the investigators involved in the study, particularly Drs. Douglas Fowlie and Donald Mowat for their helpful contributions to the clinical execution of the study in Scotland. We thank Sharon Eastwood, Parexel, for assistance in preparing initial drafts of the manuscript. We acknowledge constructive comments provided by Professors G. Wilcock and S. Gauthier on drafts of the article. CMW, CRH, and JMDS are officers of, and hold beneficial interests in, TauRx Therapeutics. RTS, PB, KK, and DJW are paid consultants to TauRx Therapeutics. The study was financed entirely by TauRx TherapeuticsPeer reviewedPublisher PD

Uncertainty in geological interpretations : Effectiveness of expert elicitations

We would like to thank all those who took part in our elicitations, as well as all those who helped in their facilitation. This work was undertaken while C.H. Randle held a joint University of Aberdeen, College of Physical Science Ph.D. Award and British Geological Survey University Funding Initiative (BUFI) Ph.D. Studentship at Aberdeen University, through Natural Environment Research Council (NERC). The contributions by C.H. Randle, R.M. Lark, and A.A. Monaghan are published with the permission of the Executive Director of BGS (NERC). The authors would like to thank Hazel Gibson and an anonymous reviewer for their comments on the manuscript and confirm that all views expressed are the opinions of the authors.Peer reviewedPublisher PD

Can uncertainty in geological cross-section interpretations be quantified and predicted?

This work was undertaken while C.H. Randle held a joint British Geological Survey University Funding Initiative (BUFI) and University of Aberdeen, College of Physical Sciences Ph.D. Studentship at Aberdeen University. The contributions by C.H. Randle, R.M. Lark, and A.A. Monaghan are published with the permission of the Executive Director of the British Geological Survey Natural Environment Research Council. We would also like to thank all those who took part in both experiments as well as the many people who have given input on our results.Peer reviewedPublisher PD

Structure-based inhibitors of amyloid beta core suggest a common interface with tau.

Alzheimer's disease (AD) pathology is characterized by plaques of amyloid beta (Aβ) and neurofibrillary tangles of tau. Aβ aggregation is thought to occur at early stages of the disease, and ultimately gives way to the formation of tau tangles which track with cognitive decline in humans. Here, we report the crystal structure of an Aβ core segment determined by MicroED and in it, note characteristics of both fibrillar and oligomeric structure. Using this structure, we designed peptide-based inhibitors that reduce Aβ aggregation and toxicity of already-aggregated species. Unexpectedly, we also found that these inhibitors reduce the efficiency of Aβ-mediated tau aggregation, and moreover reduce aggregation and self-seeding of tau fibrils. The ability of these inhibitors to interfere with both Aβ and tau seeds suggests these fibrils share a common epitope, and supports the hypothesis that cross-seeding is one mechanism by which amyloid is linked to tau aggregation and could promote cognitive decline

Birefringent properties of cyclic block copolymers and low-retardation-film development

Cyclic block copolymers (CBCs) are a new class of optical polymers made by fully hydrogenating block copolymers of styrene and conjugated diene. This class of materials has excellent optical transparency, photostability, and good thermal resistance. By changing the copolymer composition and the resulting block-copolymer morphology, a unique set of birefringence properties can be achieved. The focus of this work was to study various sources of birefringence in block copolymers using a series of model CBC materials. One particularly interesting finding relates to the development of an ultra-low-phase-retardation CBC film. Unlike the conventional approach of using an additive or blend, a CBC film prepared by melt extrusion can readily achieve near-zero retardation in both the film plane and thickness direction. This nearly isotropic CBC film is useful as a polarizer protection film in flat-panel displays. When used as the inner protective layer of a polarizer, CBC film helps to reduce the color shift of IPS-LCDs at oblique angles and offer a wider viewing angle

Randomized trial comparing proactive, high-dose versus reactive, low-dose intravenous iron supplementation in hemodialysis (PIVOTAL) : Study design and baseline data

Background: Intravenous (IV) iron supplementation is a standard maintenance treatment for hemodialysis (HD) patients, but the optimum dosing regimen is unknown. Methods: PIVOTAL (Proactive IV irOn Therapy in hemodiALysis patients) is a multicenter, open-label, blinded endpoint, randomized controlled (PROBE) trial. Incident HD adults with a serum ferritin 700 μg/L and/or TSAT ≥40%) or a reactive, low-dose IV iron arm (iron sucrose administered if ferritin <200 μg/L or TSAT < 20%). We hypothesized that proactive, high-dose IV iron would be noninferior to reactive, low-dose IV iron for the primary outcome of first occurrence of nonfatal myocardial infarction (MI), nonfatal stroke, hospitalization for heart failure or death from any cause. If noninferiority is confirmed with a noninferiority limit of 1.25 for the hazard ratio of the proactive strategy relative to the reactive strategy, a test for superiority will be carried out. Secondary outcomes include infection-related endpoints, ESA dose requirements, and quality-of-life measures. As an event-driven trial, the study will continue until at least 631 primary outcome events have accrued, but the expected duration of follow-up is 2-4 years. Results: Of the 2,589 patients screened across 50 UK sites, 2,141 (83%) were randomized. At baseline, 65.3% were male, the median age was 65 years, and 79% were white. According to eligibility criteria, all patients were on ESA at screening. Prior stroke and MI were present in 8 and 9% of the cohort, respectively, and 44% of patients had diabetes at baseline. Baseline data for the randomized cohort were generally concordant with recent data from the UK Renal Registry. Conclusions: PIVOTAL will provide important information about the optimum dosing of IV iron in HD patients representative of usual clinical practice. Trial Registration: EudraCT number: 2013-002267-25.Peer reviewedFinal Published versio